2019

Onxeo Reports Full-Year 2018 Financial Results and Provides Business Update

Clinical development of AsiDNA™ continues in phase 1 study DRIIV-1 Activity of AsiDNA™ demonstrated through the marked activation of its cellular targets enabling the determination of active doses and favorable tolerance profile Impending initiation of a phase 1b study in combination with platinum-based chemotherapy and paclitaxel; preliminary results expected before year-end 2019 New lead compound sourced from platON™ ready to…read more →

Onxeo to Present Five Preclinical Studies Highlighting AsiDNA™ Unique Profile and its clinical potential in Oncology at 2019 American Association for Cancer Research Annual Meeting

Paris (France), February 13, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR) in oncology, in particular against rare or resistant cancers, today announced that results of five preclinical study supporting the differentiated profile of…read more →

Onxeo Announces Identification of Predictive Biomarkers for AsiDNA™, its First-in-Class DNA Damage Response Inhibitor

Biomarkers correlated to tumoral sensitivity to AsiDNA™, supporting personalized medicine approaches A selection tool to screen patients in future clinical development of AsiDNA™ based on these predictive biomarkers of response   Paris (France), January 3, 2019 – 6.00 pm CET – Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development…read more →